Fermata Advisors LLC Has $330,000 Stake in Abbott Laboratories (NYSE:ABT)

Fermata Advisors LLC grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 17.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,915 shares of the healthcare product maker’s stock after acquiring an additional 423 shares during the quarter. Fermata Advisors LLC’s holdings in Abbott Laboratories were worth $330,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Edgestream Partners L.P. increased its stake in shares of Abbott Laboratories by 506.9% in the 2nd quarter. Edgestream Partners L.P. now owns 15,987 shares of the healthcare product maker’s stock valued at $1,661,000 after acquiring an additional 13,353 shares in the last quarter. Intech Investment Management LLC grew its holdings in Abbott Laboratories by 10.0% in the second quarter. Intech Investment Management LLC now owns 35,323 shares of the healthcare product maker’s stock worth $3,670,000 after purchasing an additional 3,200 shares during the period. Ieq Capital LLC increased its stake in Abbott Laboratories by 2.0% in the second quarter. Ieq Capital LLC now owns 108,990 shares of the healthcare product maker’s stock valued at $11,325,000 after purchasing an additional 2,154 shares in the last quarter. GM Advisory Group LLC raised its holdings in shares of Abbott Laboratories by 2.4% during the second quarter. GM Advisory Group LLC now owns 4,979 shares of the healthcare product maker’s stock valued at $517,000 after purchasing an additional 116 shares during the period. Finally, Clifford Group LLC grew its stake in shares of Abbott Laboratories by 1.8% in the 2nd quarter. Clifford Group LLC now owns 5,756 shares of the healthcare product maker’s stock valued at $598,000 after buying an additional 103 shares during the period. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Down 0.4 %

Shares of ABT stock opened at $113.45 on Friday. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $121.64. The company’s fifty day simple moving average is $115.00 and its two-hundred day simple moving average is $112.66. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The stock has a market capitalization of $196.78 billion, a price-to-earnings ratio of 34.48, a PEG ratio of 2.40 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.01. The business had revenue of $10.64 billion for the quarter, compared to analysts’ expectations of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 EPS. As a group, analysts anticipate that Abbott Laboratories will post 4.67 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a $0.59 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a dividend yield of 2.08%. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 66.87%.

Wall Street Analyst Weigh In

ABT has been the topic of a number of research reports. Sanford C. Bernstein upped their price target on Abbott Laboratories from $133.00 to $138.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Morgan Stanley increased their target price on Abbott Laboratories from $107.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 17th. UBS Group lifted their price target on shares of Abbott Laboratories from $143.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Oppenheimer assumed coverage on shares of Abbott Laboratories in a report on Tuesday, October 8th. They set an “outperform” rating and a $130.00 price objective on the stock. Finally, Piper Sandler boosted their target price on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an “overweight” rating in a research report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $131.57.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.